STSA — Satsuma Pharmaceuticals Share News
0.000.00%
Last trade - 00:00HealthcareSpeculativeMicro Cap
Commencement Of Tender Offer For Satsuma Pharmaceuticals, Inc In U.S.
Brief: Satsuma Pharmaceuticals Says Received Letter Notifying Co Regained Compliance With Nasdaq
U.S. STOCKS ON THE MOVE-Alphabet Inc, BlackRock, Moderna
Satsuma Pharma soars on buyout deal from Japan's Shin Nippon
Snbl Enters Into Definitive Agreement To Acquire Satsuma Pharmaceuticals
Brief: Satsuma Pharmaceuticals Reports Fourth Quarter And Full Year 2022 Financial Results And Recent Business Highlights
Satsuma Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Satsuma Pharmaceuticals Inc expected to post a loss of 36 cents a share - Earnings Preview
Satsuma Pharma rises on latest data on migraine drug candidate
Brief: Satsuma Pharmaceuticals Provides Sts101 Development Program And Corporate Update
Brief: Bml Investment Partners Lp Reports 19.4% Passive Stake In Satsuma Pharmaceuticals Inc As Of November 14 - SEC Filing
U.S. RESEARCH ROUNDUP-Calithera Biosciences, Haynes International, Lumos Pharma
Satsuma Pharma slumps as migraine drug fails late-stage study
Brief: Satsuma Pharmaceuticals Announces Topline Results From Summit Phase 3 Trial Of STS101
Satsuma Pharma slumps as migraine drug fails late-stage study
Satsuma Pharma's migraine drug fails in late-stage study (updated)
Satsuma Pharma's migraine drug fails in late-stage study
Satsuma Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary
Brief: Satsuma Pharmaceuticals - On Nov 3, Co Entered Into At-The-Market Sales Agreement, Pursuant To Which Co May Offer & Sell Shares Of Co’S Common Stock